*Optimal dilutions/concentrations should be determined by the researcher.
Not tested in other applications.
This antibody recognizes specifically an intracellular domain of the EGF receptor.
Ascites, 15 mM sodium azide
Store as concentrated solution. Centrifuge briefly prior to opening vial. For short-term storage (1-2 weeks), store at 4ºC. For long-term storage, aliquot and store at -20ºC or below. Avoid multiple freeze-thaw cycles.
synthetically produced residues 985-996 of the human EGF receptor.
For laboratory use only. Not for any clinical, therapeutic, or diagnostic use in humans or animals. Not for animal or human consumption.
epidermal growth factor receptor , ERBB , ERBB1 , HER1 , NISBD2 , PIG61 , mENA
Cell membrane,Endoplasmic reticulum membrane,Endosome,Endosome membrane,Nucleus
The receptor for Epidermal Growth Factor is an integral cell membrane protein of 170 kD, which spans the membranes of a wide range of normal and malignant epithelial cells. It is a tyrosine-specific protein kinase with the capacity to phosphorylate tyrosine residues located near its carboxy-terminus. EGF-R has anextracellular region which binds EGF and consequently mediates the initial response of cells to EGF and an intra-cellular region which posseses the tyrosine kinase activity. As a result of EGF binding to its specific receptor, there is increased DNA synthesis as well as other events including cell proliferation, differentiation and repair of damaged epithelial tissue. The EGF-R has a half-life of approximately 10 hours in human fibroblasts, but in the presence of EGF this value is reduced to about 1 hour. A close similarity has been found between the sequence of the v-erb-B oncogene and the cytoplasmic and transmembrane part of the EGF-R (truncatedEGF-R). It is hypothesized that an inappropriate activation of the human erb-B gene either by truncation or overexpression plays a role in the development of the malignancy. This hypothesis is supported by studies, which have shown an increased number of EGF-R in various malignant tumors. High levels of EGF-R have been identified in sarcomas, gliomas, gynecological, breast, bladder, and lung tumors.